Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents. 2016

Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
Department of Chemistry and Biochemistry, Florida International University, Miami, Florida, USA.

Bacterial topoisomerase functions are required for regulation of DNA supercoiling and overcoming the DNA topological barriers that are encountered during many vital cellular processes. DNA gyrase and topoisomerase IV of the type IIA bacterial topoisomerase family are important clinical targets for antibacterial therapy. Topoisomerase I, belonging to the type IA topoisomerase family, has recently been validated as a potential antitubercular target. The topoisomerase I activity has been shown to be essential for bacterial viability and infection in a murine model of tuberculosis. Mixture-based combinatorial libraries were screened in this study to identify novel bacterial topoisomerase I inhibitors. Using positional-scanning deconvolution, selective small-molecule inhibitors of bacterial topoisomerase I were identified starting from a polyamine scaffold. Antibacterial assays demonstrated that four of these small-molecule inhibitors of bacterial topoisomerase I are bactericidal against Mycobacterium smegmatis and Mycobacterium tuberculosis The MICs for growth inhibition of M. smegmatis increased with overexpression of recombinant M. tuberculosis topoisomerase I, consistent with inhibition of intracellular topoisomerase I activity being involved in the antimycobacterial mode of action.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D059004 Topoisomerase I Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE I. DNA Topoisomerase I Inhibitor,DNA Topoisomerase III Inhibitor,DNA Topoisomerase III Inhibitors,DNA Type 1 Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitors,Topoisomerase 1 Inhibitor,Topoisomerase 1 Inhibitors,Topoisomerase 3 Inhibitor,Topoisomerase 3 Inhibitors,Topoisomerase I Inhibitor,Topoisomerase III Inhibitor,Topoisomerase III Inhibitors,DNA Topoisomerase I Inhibitors,DNA Type 1 Topoisomerase Inhibitors,1 Inhibitor, Topoisomerase,3 Inhibitor, Topoisomerase,3 Inhibitors, Topoisomerase,I Inhibitor, Topoisomerase,III Inhibitor, Topoisomerase,III Inhibitors, Topoisomerase,Inhibitor, Topoisomerase 1,Inhibitor, Topoisomerase 3,Inhibitor, Topoisomerase I,Inhibitor, Topoisomerase III,Inhibitors, Topoisomerase 1,Inhibitors, Topoisomerase 3,Inhibitors, Topoisomerase I,Inhibitors, Topoisomerase III
D020102 Mycobacterium smegmatis A rapid-growing, nonphotochromogenic species of MYCOBACTERIUM originally isolated from human smegma and found also in soil and water. (From Dorland, 28th ed)
D027081 DNA Gyrase A bacterial DNA topoisomerase II that catalyzes ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. Gyrase binds to DNA as a heterotetramer consisting of two A and two B subunits. In the presence of ATP, gyrase is able to convert the relaxed circular DNA duplex into a superhelix. In the absence of ATP, supercoiled DNA is relaxed by DNA gyrase. DNA Gyrase A Subunit,DNA Gyrase B Subunit,DNA-Gyrase,GyrA Protein,GyrB Protein
D027101 DNA Topoisomerase IV A bacterial DNA topoisomerase II that catalyzes ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. Topoisomerase IV binds to DNA as a heterotetramer consisting 2 parC and 2 parE subunits. Topoisomerase IV is a decatenating enzyme that resolves interlinked daughter chromosomes following DNA replication. parC Protein,parE Protein,Topo IV,Topoisomerase IV,Topoisomerase IV Subunit A,Topoisomerase IV Subunit B,parC Gene Product,parC Gene Product, Topo IV,parE Gene Product,parE Gene Product, Topo IV,Topoisomerase IV, DNA

Related Publications

Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
March 2015, Antimicrobial agents and chemotherapy,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
March 2004, Current oncology reports,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
January 2002, Journal of medicinal chemistry,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
March 2001, Current oncology reports,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
August 2018, Molecular pharmacology,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
January 2006, Journal of medicinal chemistry,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
January 2021, Current molecular medicine,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
May 2009, Expert opinion on therapeutic patents,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
January 2011, Bioorganic & medicinal chemistry,
Shayna Sandhaus, and Thirunavukkarasu Annamalai, and Greg Welmaker, and Richard A Houghten, and Carlos Paz, and Pamela K Garcia, and Angelo Andres, and Gagandeep Narula, and Carolina Rodrigues Felix, and Sandra Geden, and Mandy Netherton, and Rashmi Gupta, and Kyle H Rohde, and Marc A Giulianotti, and Yuk-Ching Tse-Dinh
September 2008, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!